| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 32 | 2023 | 94 | 6.530 |
Why?
|
| Esophagectomy | 16 | 2019 | 53 | 4.720 |
Why?
|
| Adenocarcinoma | 22 | 2023 | 365 | 3.250 |
Why?
|
| Hernia, Hiatal | 10 | 2017 | 29 | 3.020 |
Why?
|
| Herniorrhaphy | 5 | 2017 | 71 | 2.120 |
Why?
|
| Pneumonectomy | 10 | 2021 | 129 | 2.060 |
Why?
|
| Laparoscopy | 10 | 2017 | 490 | 1.980 |
Why?
|
| Barrett Esophagus | 11 | 2023 | 31 | 1.700 |
Why?
|
| Anastomotic Leak | 3 | 2019 | 36 | 1.500 |
Why?
|
| Lung Neoplasms | 13 | 2016 | 704 | 1.470 |
Why?
|
| Neoplasm Staging | 17 | 2019 | 544 | 1.390 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2016 | 184 | 1.390 |
Why?
|
| Postoperative Complications | 10 | 2021 | 1322 | 1.340 |
Why?
|
| Neoadjuvant Therapy | 7 | 2019 | 102 | 1.320 |
Why?
|
| Lymph Nodes | 3 | 2016 | 232 | 1.270 |
Why?
|
| Pneumothorax | 2 | 2021 | 49 | 1.270 |
Why?
|
| Propensity Score | 7 | 2021 | 189 | 1.110 |
Why?
|
| Esophagogastric Junction | 4 | 2015 | 15 | 1.090 |
Why?
|
| Gastroesophageal Reflux | 5 | 2014 | 92 | 1.060 |
Why?
|
| Surgical Mesh | 3 | 2017 | 60 | 0.980 |
Why?
|
| Peer Review, Research | 2 | 2017 | 47 | 0.980 |
Why?
|
| Editorial Policies | 2 | 2017 | 54 | 0.970 |
Why?
|
| Esophagoscopy | 6 | 2015 | 26 | 0.950 |
Why?
|
| Aged | 46 | 2021 | 14949 | 0.920 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2016 | 373 | 0.900 |
Why?
|
| Biomarkers, Tumor | 8 | 2019 | 524 | 0.900 |
Why?
|
| Patient Readmission | 2 | 2021 | 448 | 0.830 |
Why?
|
| Male | 56 | 2021 | 31020 | 0.820 |
Why?
|
| Humans | 80 | 2023 | 65168 | 0.800 |
Why?
|
| Middle Aged | 46 | 2021 | 18252 | 0.780 |
Why?
|
| Stomach Neoplasms | 4 | 2017 | 81 | 0.750 |
Why?
|
| Female | 54 | 2021 | 33982 | 0.750 |
Why?
|
| Decision Support Techniques | 2 | 2015 | 194 | 0.730 |
Why?
|
| Thymoma | 4 | 2014 | 12 | 0.720 |
Why?
|
| Thymus Neoplasms | 4 | 2014 | 22 | 0.710 |
Why?
|
| Lymphatic Metastasis | 4 | 2016 | 90 | 0.710 |
Why?
|
| Esophagus | 4 | 2015 | 47 | 0.650 |
Why?
|
| Omentum | 1 | 2019 | 14 | 0.620 |
Why?
|
| Fundoplication | 5 | 2014 | 26 | 0.620 |
Why?
|
| Retrospective Studies | 26 | 2019 | 6859 | 0.620 |
Why?
|
| Risk Factors | 17 | 2020 | 5425 | 0.590 |
Why?
|
| Lung Diseases | 1 | 2020 | 183 | 0.560 |
Why?
|
| Thymectomy | 3 | 2014 | 35 | 0.560 |
Why?
|
| Length of Stay | 3 | 2021 | 827 | 0.540 |
Why?
|
| Risk Assessment | 6 | 2021 | 2098 | 0.540 |
Why?
|
| Lymph Node Excision | 2 | 2014 | 45 | 0.540 |
Why?
|
| Biopsy | 4 | 2016 | 454 | 0.530 |
Why?
|
| Thoracic Surgery, Video-Assisted | 7 | 2016 | 62 | 0.520 |
Why?
|
| Pharynx | 2 | 2015 | 25 | 0.510 |
Why?
|
| Data Accuracy | 1 | 2017 | 31 | 0.500 |
Why?
|
| Treatment Outcome | 17 | 2017 | 5783 | 0.500 |
Why?
|
| Suture Techniques | 2 | 2015 | 94 | 0.500 |
Why?
|
| Survival Rate | 10 | 2016 | 843 | 0.500 |
Why?
|
| Writing | 1 | 2017 | 42 | 0.490 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 16 | 0.480 |
Why?
|
| Mediastinum | 1 | 2016 | 28 | 0.480 |
Why?
|
| Disease Management | 2 | 2016 | 235 | 0.470 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 156 | 0.470 |
Why?
|
| Lymphadenopathy | 1 | 2016 | 23 | 0.470 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2016 | 38 | 0.470 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 66 | 0.470 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 44 | 0.470 |
Why?
|
| Pathology | 1 | 2015 | 12 | 0.460 |
Why?
|
| Bronchoscopy | 1 | 2016 | 86 | 0.460 |
Why?
|
| Gastroplasty | 3 | 2011 | 14 | 0.460 |
Why?
|
| Pneumonia, Aspiration | 1 | 2015 | 15 | 0.460 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2016 | 42 | 0.450 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 261 | 0.450 |
Why?
|
| Anesthesia, General | 1 | 2015 | 47 | 0.450 |
Why?
|
| Esophageal Perforation | 1 | 2015 | 4 | 0.450 |
Why?
|
| Minimally Invasive Surgical Procedures | 6 | 2016 | 127 | 0.450 |
Why?
|
| Respiratory Tract Fistula | 1 | 2015 | 3 | 0.450 |
Why?
|
| Pharyngeal Diseases | 1 | 2015 | 11 | 0.440 |
Why?
|
| Tracheal Diseases | 1 | 2015 | 11 | 0.440 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 124 | 0.440 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 88 | 0.440 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 57 | 0.430 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 232 | 0.430 |
Why?
|
| Proton Pump Inhibitors | 2 | 2011 | 47 | 0.420 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 178 | 0.420 |
Why?
|
| Foreign Bodies | 1 | 2015 | 55 | 0.420 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2015 | 90 | 0.420 |
Why?
|
| Hospital Costs | 1 | 2015 | 126 | 0.420 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2016 | 317 | 0.410 |
Why?
|
| Mucin-2 | 1 | 2013 | 3 | 0.410 |
Why?
|
| Laryngeal Diseases | 1 | 2013 | 2 | 0.410 |
Why?
|
| Endoscopy, Digestive System | 1 | 2013 | 33 | 0.400 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2015 | 144 | 0.390 |
Why?
|
| Prognosis | 12 | 2016 | 1783 | 0.390 |
Why?
|
| Precancerous Conditions | 3 | 2023 | 73 | 0.390 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 169 | 0.380 |
Why?
|
| Chylothorax | 1 | 2012 | 2 | 0.360 |
Why?
|
| Time Factors | 8 | 2021 | 3873 | 0.360 |
Why?
|
| Aged, 80 and over | 20 | 2019 | 5606 | 0.350 |
Why?
|
| Incidence | 5 | 2016 | 1419 | 0.350 |
Why?
|
| Quality Improvement | 1 | 2016 | 464 | 0.340 |
Why?
|
| Quality of Life | 4 | 2017 | 1257 | 0.340 |
Why?
|
| Stents | 1 | 2015 | 498 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 463 | 0.330 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2015 | 415 | 0.300 |
Why?
|
| Pennsylvania | 4 | 2016 | 66 | 0.290 |
Why?
|
| Recurrence | 3 | 2017 | 655 | 0.280 |
Why?
|
| Prospective Studies | 6 | 2019 | 3310 | 0.270 |
Why?
|
| Bile Reflux | 1 | 2007 | 1 | 0.260 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1113 | 0.250 |
Why?
|
| Bile Acids and Salts | 1 | 2007 | 25 | 0.250 |
Why?
|
| SEER Program | 4 | 2014 | 75 | 0.250 |
Why?
|
| Mutation | 2 | 2014 | 2655 | 0.240 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 2478 | 0.220 |
Why?
|
| Cohort Studies | 7 | 2017 | 2618 | 0.220 |
Why?
|
| Reoperation | 3 | 2015 | 301 | 0.220 |
Why?
|
| Adult | 21 | 2019 | 17331 | 0.220 |
Why?
|
| Carcinoma | 2 | 2016 | 130 | 0.210 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 414 | 0.210 |
Why?
|
| Comorbidity | 3 | 2016 | 1119 | 0.190 |
Why?
|
| Anastomosis, Surgical | 2 | 2014 | 118 | 0.190 |
Why?
|
| Chromosomal Instability | 2 | 2023 | 20 | 0.180 |
Why?
|
| B7-H1 Antigen | 3 | 2017 | 60 | 0.180 |
Why?
|
| Chemoradiotherapy | 2 | 2019 | 75 | 0.180 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 929 | 0.180 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 244 | 0.170 |
Why?
|
| Tumor Burden | 3 | 2017 | 75 | 0.170 |
Why?
|
| Proportional Hazards Models | 4 | 2015 | 740 | 0.160 |
Why?
|
| Hospital Mortality | 2 | 2016 | 872 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 440 | 0.160 |
Why?
|
| Prevalence | 3 | 2013 | 1445 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 287 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 35 | 0.150 |
Why?
|
| Age Factors | 4 | 2016 | 1584 | 0.150 |
Why?
|
| Smokers | 1 | 2019 | 117 | 0.140 |
Why?
|
| Genomics | 2 | 2023 | 384 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 1554 | 0.140 |
Why?
|
| Wound Healing | 1 | 2019 | 193 | 0.140 |
Why?
|
| Immunohistochemistry | 6 | 2016 | 894 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 141 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 222 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2017 | 24 | 0.130 |
Why?
|
| DNA Copy Number Variations | 2 | 2017 | 72 | 0.130 |
Why?
|
| Disease Progression | 4 | 2023 | 1219 | 0.130 |
Why?
|
| Patient Positioning | 2 | 2015 | 50 | 0.130 |
Why?
|
| DNA Damage | 1 | 2019 | 297 | 0.130 |
Why?
|
| Tobacco Use Disorder | 1 | 2019 | 247 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2021 | 519 | 0.130 |
Why?
|
| Quality Control | 1 | 2017 | 79 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 39 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2016 | 68 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 42 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 32 | 0.120 |
Why?
|
| Mediastinoscopy | 1 | 2016 | 8 | 0.120 |
Why?
|
| False Negative Reactions | 1 | 2016 | 41 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2017 | 129 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2016 | 38 | 0.120 |
Why?
|
| Forced Expiratory Volume | 1 | 2016 | 212 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 195 | 0.120 |
Why?
|
| Diverticulum, Esophageal | 1 | 2015 | 1 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 54 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 49 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 53 | 0.120 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2015 | 2 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2015 | 26 | 0.110 |
Why?
|
| Smad4 Protein | 1 | 2015 | 5 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2014 | 161 | 0.110 |
Why?
|
| Exome | 1 | 2015 | 69 | 0.110 |
Why?
|
| Morbidity | 1 | 2015 | 110 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 2703 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1163 | 0.110 |
Why?
|
| Delphi Technique | 1 | 2015 | 112 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2017 | 307 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2019 | 552 | 0.110 |
Why?
|
| Sex Factors | 2 | 2015 | 991 | 0.100 |
Why?
|
| Esophageal Diseases | 1 | 2014 | 16 | 0.100 |
Why?
|
| Mucin-6 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2015 | 309 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2019 | 1549 | 0.100 |
Why?
|
| Mucin 5AC | 1 | 2013 | 9 | 0.100 |
Why?
|
| Leiomyoma | 1 | 2014 | 18 | 0.100 |
Why?
|
| Cell Membrane | 1 | 2016 | 505 | 0.100 |
Why?
|
| Thoracoscopy | 1 | 2014 | 29 | 0.100 |
Why?
|
| Mucin-1 | 1 | 2013 | 13 | 0.100 |
Why?
|
| United States | 3 | 2019 | 8209 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 40 | 0.100 |
Why?
|
| Acute Disease | 1 | 2015 | 662 | 0.100 |
Why?
|
| Aneuploidy | 1 | 2014 | 42 | 0.100 |
Why?
|
| Calcinosis | 1 | 2014 | 84 | 0.100 |
Why?
|
| Young Adult | 8 | 2019 | 4811 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 984 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1222 | 0.100 |
Why?
|
| Global Health | 1 | 2014 | 181 | 0.100 |
Why?
|
| ErbB Receptors | 3 | 2014 | 127 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 182 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 213 | 0.090 |
Why?
|
| Hospitalization | 1 | 2019 | 1391 | 0.090 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2012 | 18 | 0.090 |
Why?
|
| Thoracotomy | 1 | 2012 | 47 | 0.090 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2011 | 4 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2756 | 0.090 |
Why?
|
| Hypopharynx | 1 | 2011 | 4 | 0.090 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2012 | 21 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 33 | 0.090 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 52 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 272 | 0.090 |
Why?
|
| Oregon | 1 | 2011 | 19 | 0.090 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2011 | 74 | 0.080 |
Why?
|
| Scoliosis | 1 | 2010 | 10 | 0.080 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 16 | 0.080 |
Why?
|
| Patient Selection | 2 | 2012 | 483 | 0.070 |
Why?
|
| Logistic Models | 1 | 2013 | 1269 | 0.070 |
Why?
|
| Cardia | 1 | 2008 | 1 | 0.070 |
Why?
|
| Larynx | 1 | 2008 | 15 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 2293 | 0.070 |
Why?
|
| Algorithms | 1 | 2013 | 1046 | 0.070 |
Why?
|
| Radiography | 1 | 2008 | 555 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 1560 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 222 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2019 | 324 | 0.060 |
Why?
|
| North America | 2 | 2016 | 114 | 0.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2017 | 64 | 0.060 |
Why?
|
| Europe | 2 | 2016 | 199 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 464 | 0.060 |
Why?
|
| Lung | 1 | 2010 | 964 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 94 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1140 | 0.050 |
Why?
|
| Genes, jun | 1 | 2003 | 3 | 0.050 |
Why?
|
| Epidermis | 1 | 2003 | 35 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2012 | 59 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2013 | 576 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 851 | 0.040 |
Why?
|
| Biomarkers | 2 | 2017 | 1479 | 0.040 |
Why?
|
| Keratins | 2 | 2014 | 31 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 220 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 72 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 96 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 9 | 0.030 |
Why?
|
| Thorax | 1 | 2015 | 35 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 27 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2015 | 53 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2015 | 36 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 66 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 122 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2015 | 39 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2015 | 32 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2015 | 146 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2015 | 26 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 198 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 168 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 660 | 0.030 |
Why?
|
| Paris | 1 | 2014 | 5 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 178 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 50 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 213 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 2014 | 43 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 574 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 7 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2013 | 20 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 31 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2014 | 72 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 583 | 0.020 |
Why?
|
| Animals | 4 | 2015 | 21292 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 120 | 0.020 |
Why?
|
| Sirtuin 2 | 1 | 2013 | 6 | 0.020 |
Why?
|
| Anemia | 1 | 2014 | 132 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 361 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2013 | 108 | 0.020 |
Why?
|
| Tripartite Motif Proteins | 1 | 2013 | 41 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 108 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 113 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2015 | 302 | 0.020 |
Why?
|
| Supine Position | 1 | 2012 | 34 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 320 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2011 | 37 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 133 | 0.020 |
Why?
|
| Causality | 1 | 2011 | 60 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 236 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 92 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 729 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 372 | 0.020 |
Why?
|
| Catheterization | 1 | 2011 | 111 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 326 | 0.020 |
Why?
|
| Endoscopy | 1 | 2011 | 95 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 344 | 0.020 |
Why?
|
| Safety Management | 1 | 2012 | 136 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1695 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 6296 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 861 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2010 | 40 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 882 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2013 | 714 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1094 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 170 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2008 | 61 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 602 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 981 | 0.020 |
Why?
|
| Mice | 2 | 2015 | 11095 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 3139 | 0.010 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2003 | 2 | 0.010 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2003 | 9 | 0.010 |
Why?
|
| Eyelids | 1 | 2003 | 9 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2003 | 23 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2003 | 46 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 49 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2003 | 41 | 0.010 |
Why?
|
| Keratinocytes | 1 | 2003 | 71 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 156 | 0.010 |
Why?
|
| Critical Pathways | 1 | 2002 | 30 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2003 | 310 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 449 | 0.010 |
Why?
|
| Cell Movement | 1 | 2003 | 480 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2002 | 199 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 1282 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 2186 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 1653 | 0.010 |
Why?
|
| Veterans | 1 | 2002 | 761 | 0.010 |
Why?
|